Alnylam Pharmaceuticals (ALNY) EPS: History & Chart

Alnylam Pharmaceuticals, Inc.(ALNY)

Biotechnology · Cambridge, MA

$237.10+0.54 (+0.23%)

At close: Aug 28, 2026, 4:00 PM ET

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.

Cambridge, MA

2,500 employees

www.alnylam.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Yvonne L. Greenstreet

View full financials

ALNY Earnings Per Share (EPS) Metrics

EARNINGS PER SHARE (EPS)

5.92

EARNINGS PER SHARE (EPS) AVG TTM

0.10

EARNINGS PER SHARE (EPS) AVG 3Y

-3.15

EARNINGS PER SHARE (EPS) AVG 5Y

-4.54

EARNINGS PER SHARE (EPS) AVG 10Y

-5.15

EARNINGS PER SHARE (EPS) AVG 15Y

-4.21

EARNINGS PER SHARE (EPS) AVG 20Y

-3.55

CURRENT VS TTM AVG

+5538.10%

CURRENT VS 3Y AVG

+287.79%

CURRENT VS 5Y AVG

+230.25%

CURRENT VS 10Y AVG

+215.03%

CURRENT VS 15Y AVG

+240.49%

CURRENT VS 20Y AVG

+266.96%

NAME	MARKET CAP	EARNINGS PER SHARE (EPS)	TTM	3Y	5Y
Alnylam Pharmaceuticals, Inc. (ALNY)	$31.73B	5.92	0.10	-3.15	-4.54
Centene Corp. (CNC)vs ›	$31.99B	-10.44	-3.64	-0.05	0.88
Biogen Inc. (BIIB)vs ›	$32.28B	5.65	10.02	12.26	14.06
GE HealthCare Technologies Inc. (GEHC)vs ›	$32.40B	3.45	4.46	4.05	4.25
Zoetis Inc. (ZTS)vs ›	$32.42B	6.07	5.75	5.27	4.80
Waters Corporation (WAT)vs ›	$31.02B	4.01	10.78	11.05	10.65
Medline Inc. (MDLN)vs ›	$29.83B	0.86	1.48	0.80	0.80
DexCom, Inc. (DXCM)vs ›	$34.27B	2.53	1.80	1.48	1.30
ResMed Inc. (RMD)vs ›	$34.86B	10.40	10.00	8.26	6.94
Alcon Inc. (ALC)vs ›	$35.12B	1.30	2.02	1.68	1.07

NAME

MARKET CAP

EARNINGS PER SHARE (EPS)

TTM

Alnylam Pharmaceuticals, Inc. (ALNY)

$31.73B

5.92

0.10

-3.15

-4.54

Centene Corp. (CNC)vs ›

$31.99B

-10.44

-3.64

-0.05

0.88

Biogen Inc. (BIIB)vs ›

$32.28B

5.65

10.02

12.26

14.06

GE HealthCare Technologies Inc. (GEHC)vs ›

$32.40B

3.45

4.46

4.05

4.25

Zoetis Inc. (ZTS)vs ›

$32.42B

6.07

5.75

5.27

4.80

Waters Corporation (WAT)vs ›

$31.02B

4.01

10.78

11.05

10.65

Medline Inc. (MDLN)vs ›

$29.83B

0.86

1.48

0.80

DexCom, Inc. (DXCM)vs ›

$34.27B

2.53

1.80

1.48

1.30

ResMed Inc. (RMD)vs ›

$34.86B

10.40

10.00

8.26

6.94

Alcon Inc. (ALC)vs ›

$35.12B

1.30

2.02

1.68

1.07

Earnings Per Share (EPS) FAQ

What is the earnings per share (EPS) for Alnylam Pharmaceuticals, Inc. (ALNY)?

The earnings per share (EPS) for ALNY stock is 5.92.

Is Alnylam Pharmaceuticals, Inc.'s earnings per share (EPS) high or low?

The earnings per share (EPS) of 5.92 is 230% above its 5-year average of -4.54, near the high end of its 5-year range (-9.30–5.92).

What is the TTM average earnings per share (EPS) for Alnylam Pharmaceuticals, Inc. (ALNY)?

The TTM average earnings per share (EPS) for ALNY stock is 0.10.

What is the 3Y average earnings per share (EPS) for Alnylam Pharmaceuticals, Inc. (ALNY)?

The 3Y average earnings per share (EPS) for ALNY stock is -3.15.

What is the 5Y average earnings per share (EPS) for Alnylam Pharmaceuticals, Inc. (ALNY)?

The 5Y average earnings per share (EPS) for ALNY stock is -4.54.

What is the 10Y average earnings per share (EPS) for Alnylam Pharmaceuticals, Inc. (ALNY)?

The 10Y average earnings per share (EPS) for ALNY stock is -5.15.

What is the 15Y average earnings per share (EPS) for Alnylam Pharmaceuticals, Inc. (ALNY)?

The 15Y average earnings per share (EPS) for ALNY stock is -4.21.

What is the 20Y average earnings per share (EPS) for Alnylam Pharmaceuticals, Inc. (ALNY)?

The 20Y average earnings per share (EPS) for ALNY stock is -3.55.

DATE	EARNINGS PER SHARE (EPS)
2025-12-31	2.39
2024-12-31	-2.18
2023-12-31	-3.52
2022-12-31	-9.30
2021-12-31	-7.20
2020-12-31	-7.46
2019-12-31	-8.11
2018-12-31	-7.57
2017-12-31	-5.42
2016-12-31	-4.79
2015-12-31	-3.45
2014-12-31	-4.85
2013-12-31	-1.45
2012-12-31	-2.11
2011-12-31	-1.36
2010-12-31	-1.04
2009-12-31	-1.14
2008-12-31	-0.64
2007-12-31	-2.21
2006-12-31	-1.09
2005-12-31	-1.96
2004-12-31	-2.75
2003-12-31	-26.56
2002-12-31	-12.48

DATE

EARNINGS PER SHARE (EPS)

2025-12-31

2.39

2024-12-31

-2.18

2023-12-31

-3.52

2022-12-31

-9.30

2021-12-31

-7.20

2020-12-31

-7.46

2019-12-31

-8.11

2018-12-31

-7.57

2017-12-31

-5.42

2016-12-31

-4.79

2015-12-31

-3.45

2014-12-31

-4.85

2013-12-31

-1.45

2012-12-31

-2.11

2011-12-31

-1.36

2010-12-31

-1.04

2009-12-31

-1.14

2008-12-31

-0.64

2007-12-31

-2.21

2006-12-31

-1.09

2005-12-31

-1.96

2004-12-31

-2.75

2003-12-31

-26.56

2002-12-31

-12.48

Earnings Per Share (EPS): 5.92

ALNY Earnings Per Share (EPS)

ALNY Quarterly EPS Growth (YoY)

ALNY P/E Ratio

ALNY P/E Ratio Chart

ALNY Average Earnings Per Share (EPS) Chart

ALNY Current vs Average Earnings Per Share (EPS) Chart

ALNY Earnings Per Share (EPS) Metrics

ALNY Competitors' Earnings Per Share (EPS)

EPS Comparison

Earnings Per Share (EPS) Formula & Definition

Earnings Per Share (EPS) FAQ

ALNY Earnings Per Share (EPS) History

Related Metrics

ALNY PEG Ratio

ALNY PEG Ratio Chart